SAN FRANCISCO - December 9, 2013 - Merriman Capital, Inc. ("Merriman"), a wholly owned subsidiary of Merriman Holdings, Inc. (MERR), announced today that it will host a conference call for Pressure BioSciences, Inc. ("Pressure BioSciences") (PBIO) on Thursday, December 12, 2013 at 4:30 p.m. EST. Pressure BioSciences CEO Richard T. Schumacher and Chairman Jeffrey N. Peterson will provide comments on the Company with an accompanying presentation.
All investors and interested parties are welcome to join the conference call and webcast. A question and answer session will follow the opening remarks and presentation. Mr. Schumacher, Mr. Peterson, and board members Mr. Vito Mangiardi, Mr. Kevin Pollack, and Dr. Mickey Urdea will be available during the Q&A session.
Conference Call, Webcast and Presentation Information
Date: Thursday, December 12, 2013
Time: 4:30 PM Eastern Standard Time (EST)
To listen to this teleconference via telephone (whether or not watching the webcast):
Dial-in: (800) 875-3456 (U.S.); (800) 648-0973 (Canada); (302) 607-2001 (International)
Passcode: VS87265 Conference ID: 865561
To view the webcast, use the following conference link (NOTE:you must use the call-in number above for the audio portion of the webcast): http://www.join.me/pbio.investormeeting.M1.
The PBIO presentation will be available for viewing and downloading as of 10 a.m. EST, Thursday, December 12, 2013 on the Company`s website: http://www.pressurebiosciences.com.
For those unable to participate in the live teleconference, a replay will be available approximately one hour after the call and will be accessible through the Company`s website for 30 days.
About Merriman Capital, Inc.
Merriman Capital, Inc. is a full service investment bank and Broker-Dealer that facilitates efficient capital formation through a proprietary digital network, as well as Capital Markets Advisory and comprehensive Corporate Brokerage services for public and private companies. The firm also provides equity and options execution services for sophisticated investors and differentiated research for high growth companies. Merriman Capital, Inc. is a wholly owned brokerage subsidiary of Merriman Holdings, Inc. (MERR) and is a leading advisory firm for publicly traded, high-growth companies.
Merriman Capital, Inc. is a registered broker-dealer and member of The Financial Industry Regulatory Authority (FINRA) http://www.finra.org/ and the Securities Investor Protection Corporation (SIPC) http://www.sipc.org/.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (PBIO) is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology ("PCT"). PCT is a patented, enabling technology platform with multiple applications in the estimated $6 billion life sciences sample preparation market. PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. PBI currently focuses its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for mass spectrometry, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterror applications.
Note to Investors
This press release contains certain forward-looking statements based on our current expectations, forecasts and assumptions that involve risks and uncertainties. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity. Forward-looking statements in this release are based on information available to us as of the date hereof. Our actual results may differ materially from those stated or implied in such forward-looking statements, due to risks and uncertainties associated with our business, which include the risk factors disclosed in our Form 10-K-A filed on April 30, 2013 and the Form 10-Q filed on November 14, 2013. Forward-looking statements include statements regarding our expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "should," and "would" or similar words. We assume no obligation to update the information included in this press release, whether as a result of new information, future events or otherwise. The Form 10-K-A filed on April 30, 2013 and the Form 10-Q filed on November 14, 2013, together with this press release and the financial information contained herein, are available on our website, www.merrimanco.com. Please click on "Investor Relations."
# # #
Merriman Capital, Inc.
Chief Operating Officer
Merriman Capital, Inc.
Chief Compliance Officer
Merriman Capital, Inc.
At Pressure BioSciences:
Richard T. Schumacher
President and CEO
Pressure BioSciences, Inc.
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Merriman Holdings Inc. via GlobeNewswire
- Investment & Company Information